Progress Against HIV Stalls in South Africa, New Research Reveals

**Lead**

A troubling new research study has revealed that progress in reducing new HIV infections and improving treatment outcomes in South Africa has stalled, marking a significant setback in the global fight against the virus. The findings, published by a team of epidemiologists and public health researchers, indicate that after years of steady decline, the rate of new infections has remained stubbornly static in recent years, while the number of people on antiretroviral therapy has not increased at the pace needed to meet international targets. South Africa, home to the world's largest HIV epidemic, had been seen as a beacon of hope due to its aggressive testing and treatment programmes, but the latest data suggests that momentum has been lost.

**Context**

South Africa has long been at the epicentre of the HIV pandemic. According to estimates from the Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 7.8 million people were living with HIV in the country as of 2023, making up about 20 per cent of the global total. The government, in partnership with international donors, has invested heavily in antiretroviral therapy, resulting in dramatic reductions in AIDS-related deaths over the past two decades. However, the new research, which draws on data from national health surveys and clinic records up to early 2026, suggests that the decline in new infections has flattened out since around 2020. Among young women aged 15–24, a group particularly vulnerable to infection, rates have not improved, and in some areas have even crept up. The study also points to gaps in viral load suppression, with many patients failing to adhere to long-term treatment regimens.

Several factors are believed to be contributing to the stall. The COVID-19 pandemic severely disrupted health services, diverting resources away from HIV programmes and causing many patients to miss appointments. Lockdowns and restrictions led to interruptions in the supply of antiretroviral drugs, and stigma around HIV remains a persistent barrier to testing and prevention. Furthermore, funding for global health initiatives has faced increasing pressure, with some donor countries scaling back contributions. The South African government has also grappled with challenges in its healthcare system, including staffing shortages and infrastructure deficiencies in rural areas.

**Analysis**

The stalling of progress in South Africa is deeply concerning because it undermines the global goal of ending AIDS as a public health threat by 2030. The UNAIDS 95-95-95 targets aim for 95 per cent of people living with HIV to know their status, 95 per cent of those diagnosed to be on antiretroviral therapy, and 95 per cent of those on therapy to achieve viral suppression. South Africa has made impressive strides towards these targets, but the latest research suggests that the final push is proving the hardest. Without renewed efforts, the country risks falling short, which would have repercussions across sub-Saharan Africa and beyond.

For the United Kingdom, the stagnation in South Africa has direct implications. The UK is a major donor to the Global Fund to Fight AIDS, Tuberculosis and Malaria, and has invested significantly in HIV research and programmes in southern Africa. British pharmaceutical companies and research institutions collaborate closely with South African partners. A prolonged stall could lead to higher long-term treatment costs and increased drug resistance, as incomplete suppression of the virus allows mutations to develop. Moreover, the UK's own HIV strategy, which includes a goal of zero new transmissions by 2030, is influenced by global trends. Migratory patterns and travel mean that epidemics in one region can affect others. The British government and civil society organisations must consider whether current levels of international aid and technical support are sufficient to re-energise the response.

The research also highlights the need for innovative approaches. Pre-exposure prophylaxis (PrEP) has been rolled out in South Africa, but uptake has been slow, particularly among young women. Long-acting injectable PrEP and new treatment options could offer hope, but they require investment and community engagement. Addressing structural factors such as poverty, gender inequality, and education is essential. Without a holistic strategy that combines biomedical interventions with social support, the plateau may become a permanent stagnation.

**Fontes**

This article is based on findings from a research study published in a peer-reviewed journal, as well as data and reports from UNAIDS, the World Health Organization (WHO), and the South African National Department of Health. The study is attributed to a team of epidemiologists at the University of Cape Town and the South African Medical Research Council, with funding from the National Institutes of Health and the UK Medical Research Council. All sources are publicly available and verifiable.